NCT05946460 2024-02-06
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
Clinical Trials
10 trialsNCT04922138 2023-04-21
APPOINT
Shanghai Chest Hospital
Phase 2 Unknown
NCT04519983 2023-03-20
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT04755738 2021-09-05
MWA
Qianfoshan Hospital
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04952168 2021-07-07
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Tongji Hospital
Phase 2 Unknown
NCT04905550 2021-06-02
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT04882345 2021-05-11
ACTIVE
Shanghai Chest Hospital
Phase 2 Unknown
NCT04643847 2020-11-25
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04455594 2020-07-02
ANSWER
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown